Intelligent Bio Solutions Inc. (INBS) 是一家上市公司 属于 医疗保健 板块，经营于 Medical - Diagnostics & Research 行业. 公司总部位于 New York City, NY, 美国. 现任CEO为 Harry Simeonidis.
INBS 拥有 IPO日期为 2020-12-23, 50 名全职员工, 在 NASDAQ Capital Marke, 市值为 $1.8M.
Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
